Haemonetics Corporation Presents at The Benchmark Company, LLC OneonOne Investor Conference, May-28-2015
Apr 29 15
Haemonetics Corporation Presents at The Benchmark Company, LLC OneonOne Investor Conference, May-28-2015 . Venue: The Pfister Hotel, 424 E. Wisconsin Avenue, Milwaukee, Wisconsin, United States.
Haemonetics Corporation Announces Board Changes
Apr 27 15
Haemonetics Corporation announced expanded roles for two executives. These changes are part of an ongoing plan to advance the company's global leadership in blood management solutions and to execute on strategies to enhance shareholder value. Kent Davies, who joined the company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO. In this expanded role, Mr. Davies will have overall accountability for the company's commercial, product development and product management focus across the entire portfolio and in all geographies. Byron Selman, who joined the company upon the acquisition of Pall Corporation's transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies. Mr. Selman will oversee the Company's global commercial and market development efforts, with the exception of the company's commercial Plasma business.
Berendsen plc Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Fiscal Year Ended March 28, 2015; Provides Earnings Guidance for the Fiscal 2016
Apr 27 15
Berendsen plc reported unaudited consolidated earnings results for the fourth quarter and full year ended March 28, 2015. For the quarter, the company reported net revenues of $226,478,000 compared to $241,091,000 a year ago. Operating income was of $11,538,000 compared to $12,367,000 a year ago. Income before taxes was of $9,659,000 compared to $9,755,000 a year ago. Net loss was $2,930,000 compared to net profit of $10,184,000 a year ago. Net loss per common share assuming dilution was $0.06 compared to net income per common share assuming dilution of $0.19 a year ago. GAAP cash flow from operations was $55,599,000 compared to $51,471,000 a year ago. Capital expenditures were $21,942,000 compared to $29,927,000 a year ago. Non-GAAP operating income was $35,191,000 compared to $34,236,000 a year ago. Non-GAAP income before taxes was $32,606,000 compared to $31,624,000 a year ago. Non-GAAP net income was $24,453,000 or $0.47 per diluted share compared to $24,193,000 or $0.46 per diluted share a year ago.
For the year, the company reported net revenues of $910,373,000 compared to $938,509,000 a year ago. Operating income was of $40,540,000 compared to $46,432,000 a year ago. Income before taxes was of $31,165,000 compared to $36,401,000 a year ago. Net income was $16,897,000 compared to $35,148,000 a year ago. Net income per common share assuming dilution was $0.32 compared to $0.67 a year ago. GAAP cash flow from operations was $127,430,000 compared to $139,524,000 a year ago. Capital expenditures were $122,472,000 compared to $73,648,000 a year ago. Non-GAAP operating income was $137,503,000 compared to $159,239,000 a year ago. Non-GAAP income before taxes was $128,128,000 compared to $149,208,000 a year ago. Non-GAAP net income was $96,222,000 or $1.85 per diluted share compared to $114,443,000 or $2.19 per diluted share a year ago.
Overall fiscal 2016 revenue is expected to grow 4% to 6% on a reported basis and 7% to 9% in constant currency. The Company expects strong revenue growth from its identified growth drivers of Plasma, TEG and Emerging Markets, double digit increase in Software, an emerging growth driver, and the benefit of a 53 week in fiscal 2016, partially offset by a moderating revenue headwind in the U.S. blood center business and currency weakness. Income taxes are expected to approximate 24% of pre-tax adjusted income. Adjusted earnings per share, excluding remaining VCC transformation expenses and deal amortization, are expected in the range of $1.98 to $2.08, an increase of 7% to 2% over fiscal 15. In constant currency, fiscal 2016 earnings growth is expected to be in the range of 15% to 20%. Fiscal 2016 free cash flow is expected to approximate $105 million to $110 million before funding restructuring and capital investment for transformation activities. The Company anticipates investing $27 million of free cash flow to fund the remaining capital expenditures and cash transformation expenditures to complete the VCC initiatives in fiscal 2016.